Dr. Timothy Miller, 2023 Rainwater Prize winner and Tau Consortium member, leads this @JAMANeuro article reporting long‑term Phase 3 and open‑label extension results in SOD1-ALS. Catch up on this example of bold, patient-focused science: https://t.co/MJGOUpEaJv
Loss of progranulin drives the buildup of TMEM106B fibrils in lysosomes, causing their membranes to burst. Risk variants in TMEM106B accelerate this process. @UMich@univmiami@NIH@Stanford https://t.co/vjPbtMHDkM
Dr. Leonard Petrucelli has joined the Miller School of Medicine as Founding Director of the Neuroscience Institute. Dr. Petrucelli is a visionary scientist and a global leader in neurodegeneration research. His seminal work has uncovered the molecular mechanisms underpinning Alzheimer’s disease, frontotemporal dementia and ALS. His research reveals novel biomarkers and therapeutic targets that will help shape the next generation of treatments, helping to improve the lives of patients facing these devastating diseases.
Welcome, Dr. Petrucelli! Read more: https://t.co/cg1WhyxxDb
The MBI community gathered today to honor longtime colleague Dr. David Borchelt.
Dr. Gopal Thinakaran, a close collaborator of Borchelt's, opened the First Annual David R. Borchelt Excellence in Neurodegeneration Research Seminar with a talk on BIN1’s role in Alzheimer’s.
Tracking #ALS early could transform care. Target ALS-backed scientists are developing blood & CSF tests for #CrypticPeptides—potential early biomarkers. Learn more: https://t.co/xAMWYVyuxC #ALSResearch#EveryoneLives
Dr. Leonard Petrucelli is a globally recognized leader in neurodegeneration and our longtime Scientific Advisor. He's been instrumental in shaping #ALSResearch and the very foundation of Target ALS. As he steps down from his role with us, we celebrate his partnership and vision.
NEW PAPER is out! We measured plasma p-tau217 and Aβ42/40 in 509 patients with the cognitive concerns. Worth a read if you're thinking of using blood-based biomarkers in the outpatient clinic.
https://t.co/G4Vq53DiTu
@PiuraYoav1@MayoClinic@MayoClinicNeuro@mayocliniclabs
Join us in celebrating our 2024 Cozzarelli Prize Class IV: Biomedical Sciences winning paper, “Ultrahigh frequencies of peripherally matured LGI1- and CASPR2-reactive B cells characterize the cerebrospinal fluid in autoimmune encephalitis.” Read more: https://t.co/rR16Co9a4a
When #DanDoctoroff was diagnosed with #ALS, he saw an opportunity to make change. See what inspired him to found Target ALS to accelerate the discovery, development, and path to effective treatments.
Take action today: https://t.co/gfErNMXvhL
#ALSResearch#EveryoneLives
I was thrilled for the opportunity to present today at #ADPD2025 the work @PrudencioLab, in the wonderful city of Vienna where I was lucky to get an awesome tour by Dr Wilfried Rossoll!
Very proud of this new study from the lab! 🌟We identified a novel lncRNA, FAM151B-DT, that is disrupted across neurodegenerative diseases. https://t.co/tbGEsA9BYs